WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Faculty of Pharmacy, Riga Stradins University, Riga, Latvia.
BMC Public Health. 2018 Nov 28;18(1):1322. doi: 10.1186/s12889-018-6202-2.
European legislation prohibits direct-to-consumer advertising of prescription medicines, but allows drug manufacturers to provide information to the public on health and diseases. Our aim was to measure the frequency of disease awareness campaigns in Latvian media and assess their compliance with international and European standards.
Materials on health/disease and treatments were collected between April and September 2015 from 12 newspapers and magazines and six online portals. Disease awareness campaigns were assessed using a previously developed instrument based on the WHO Ethical Criteria for Medicinal Drug promotion and European standards (EU law and pharmaceutical industry self-regulatory guidelines). Collected materials were used to examine the information provided on medical conditions and their diagnosis and treatment. The inter-rater reliability was calculated.
We collected 263 materials from print (n = 149) and online media (n = 114); 94 were news items and 169 were disease-awareness advertisements. Cancer, cardiovascular problems, allergies and respiratory diseases were common topics. Of the 157 campaigns assessed, non-compliance was identified in 149 cases (inter-rater reliability 90%), mainly due to misleading or incomplete information, lack of balance and the absence of a listed author/sponsor. Six disease awareness campaigns directly mentioned a pharmaceutical product by brand name and other four included the logo or name of a manufacturer, referred to a condition and indirectly mentioned a treatment, all in contravention with European law.
The compliance of disease awareness campaigns in Latvian media with international and European standards is low. This raises concerns about the nature of information being conveyed. Through lack of balance, missing sponsorship information, and misleading or incomplete information, these campaigns could contribute to inaccurate self-diagnosis and generate demand among those who might not need medical treatment.
欧洲立法禁止直接向消费者宣传处方药品,但允许药品制造商向公众提供有关健康和疾病的信息。我们的目的是衡量拉脱维亚媒体中疾病意识宣传活动的频率,并评估其是否符合国际和欧洲标准。
2015 年 4 月至 9 月,我们从 12 种报纸和杂志以及 6 个在线门户网站收集了有关健康/疾病和治疗的材料。使用先前根据世界卫生组织(WHO)药品促销伦理准则和欧洲标准(欧盟法律和制药行业自律准则)制定的工具评估疾病意识宣传活动。收集的材料用于检查提供的有关医疗条件及其诊断和治疗的信息。计算了组内相关系数。
我们从印刷媒体(n=149)和在线媒体(n=114)收集了 263 份材料;94 份为新闻报道,169 份为疾病意识广告。癌症、心血管问题、过敏和呼吸道疾病是常见的主题。在评估的 157 个活动中,有 149 个(组内相关系数 90%)不符合规定,主要原因是信息具有误导性或不完整、缺乏平衡以及没有列出作者/赞助商。有 6 个疾病意识宣传活动直接提到了一种药品的品牌名称,还有另外 4 个活动包含制造商的标志或名称,提及了一种病症,并间接地提到了一种治疗方法,所有这些都违反了欧洲法律。
拉脱维亚媒体中疾病意识宣传活动与国际和欧洲标准的符合率较低。这引起了人们对所传达信息性质的关注。由于缺乏平衡、缺少赞助信息、以及具有误导性或不完整的信息,这些宣传活动可能导致不准确的自我诊断,并在那些可能不需要治疗的人中产生需求。